Venture Capital

HTC's VIVERSE launches a global art contest, leveraging web technology to let anyone create and view immersive 3D art without needing a VR headset.

An Israeli startup claims its 'Artificial Expert Intelligence' autonomously achieved a 3.6x speedup over a decade of human-engineered NVIDIA code.

Holman Logistics hires Laurie Johnston, a seasoned legal and HR executive, to navigate the supply chain industry's complex talent and compliance challenges.

A next-gen drug for chronic hives shows superior, faster results than the long-standing standard of care, heralding a potential shift in allergy treatment.

MARSOC veterans secure $32M for Smack Technologies, an AI lab building a 'Decision Dominance' platform designed to reshape U.S. military strategy.

With 14% growth, strategic acquisitions, and major AI advancements, Real Chemistry is redefining healthcare commercialization on its 25th anniversary.

Halia Therapeutics is betting on a novel target to fight chronic inflammation. At a key summit, it will pitch its unique approach for cancer, obesity, and Alzheimer's.

A major contract with HawkEye 360 signals Europe's urgent push for sovereign defense, using commercial satellites to monitor invisible threats from space.

Flare Therapeutics partners with Simplicis, moving from manual "human babysitting" to automated infrastructure to eliminate risk and scale drug discovery.

The biopharma company's strategic bid for non-dilutive funding could advance a first-in-class therapy for severe, untreated skin conditions.

Diga-Talk Solutions names John K. Sullivan its new CBO, leveraging his 30 years in fire service to revolutionize mission-critical communications.

NVIDIA invests billions in optics leader Coherent to secure the high-speed, US-made components needed to power the next generation of AI factories.

For millions suffering from relentless chronic cough with no approved treatments, Trevi Therapeutics' Haduvio offers a new possibility backed by strong clinical data.

With a $41M boost from a16z, Ease Health is using AI to unify a fractured behavioral health system, promising relief for overwhelmed providers.

Following a chaotic power outage, unions and city leaders rally against Waymo, demanding answers on public safety, job security, and regulatory oversight.

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

Amid soaring uranium prices, Refined Energy begins its maiden drill program in Saskatchewan's prolific Athabasca Basin, a high-stakes bet on nuclear's future.

With a $6B M&A war chest and a new AI focus, Roper Technologies takes the stage at Morgan Stanley. Here’s what investors will be watching for.

In a strategic reverse merger with Rallybio, T-cell therapy innovator Candid Therapeutics secures over $505M to advance its groundbreaking autoimmune pipeline.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.